Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Stock Information for Melcor Developments Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Melcor Developments Ltd.

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.